1. Patients must have histological confirmation of metastatic urothelial carcinoma. Patients must have sufficient tumor tissues for future MTAP testing and research. Histological variants such as glandular, squamous, sarcomatoid, micropapillary, plasmacytoid, and small cell changes will not be allowed for this trial unless these tumors are MTAP-deficient.